Author

J. E. Comer

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 2 Immunology· 1 Pathology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Research Focus:host-pathogen & immune response· 4 Organism:non-human primate· 2 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:imaging· 1 Approach:machine learning (classical)· 1 Organism:mouse· 1

Frequent Co-Authors

T. Brasel· 3 shared A. N. Freiberg· 2 shared C. Massey· 2 shared A. D. L. R. De La Rosa· 1 shared A. Kolykhalov· 1 shared A. N. Prasad· 1 shared A. Rasmussen· 1 shared B. Gong· 1 shared

Activity by Year

2020-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersMicrobiology

T. Brasel

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

The Prophylactic and Therapeutic Efficacy of the Broadly Active Antiviral Ribonucleoside N4-Hydroxycytidine (EIDD-1931) in a Mouse Model of Lethal Ebola Virus Infection

G. R. Bluemling, S. Mao, M. G. Natchus, W. Painter, S. Mulangu, M. Lockwood, A. D. L. R. De La Rosa, T. Brasel, J. E. Comer, A. N. Freiberg, A. Kolykhalov, G. R. Painter

This study evaluates the efficacy of EIDD-1931, a ribonucleoside analog, in preventing and treating lethal Ebola virus infection in mice.

bioRxiv · Oct 18, 2022 · PreprintMicrobiology

Natural history of nonhuman primates after conjunctival exposure to Ebola virus

R. W. Cross, A. N. Prasad, C. Woolsey, K. N. Agans, V. Borisevich, N. S. Dobias, J. E. Comer, D. J. Deer, J. B. Geisbert, A. Rasmussen, W. I. Lipkin, K. A. Fenton, T. W. Geisbert

This study examines the natural history of Ebola virus infection in nonhuman primates after conjunctival exposure, finding that lower doses result in delayed disease and reduced mortality.

bioRxiv · Dec 29, 2021Microbiology

A synthetic peptide CTL vaccine targeting nucleocapsid confers protection from SARS-CoV-2 challenge in rhesus macaques

P. Harris, T. Brasel, C. Massey, C. Herst, S. Burkholz, P. Lloyd, T. Blankenberg, T. Bey, R. Carback, T. Hodge, S. Ciotlos, L. Wang, J. E. Comer, R. M. Rubsamen

A synthetic peptide vaccine targeting SARS-CoV-2 nucleocapsid protein protected rhesus macaques from viral challenge, reducing pneumonia and viral load.

bioRxiv · Apr 24, 2021Immunology

Cell-type apoptosis in lung during SARS-CoV-2 infection

Y. Liu, T. M. Garron, Q. Chang, Z. Su, C. Zhou, E. C. Gong, J. Zheng, W. Yin, T. Ksiazek, T. Brasel, Y. Jin, P. Boor, J. E. Comer, B. Gong

This study investigates cell-type apoptosis in lung tissues during SARS-CoV-2 infection, finding both intrinsic and extrinsic apoptotic pathways are activated, while some cell types remain refractory to infection.

bioRxiv · Dec 23, 2020Pathology

Pyronaridine Tetraphosphate Efficacy Against Ebola Virus Infection in Guinea Pig

T. R. Lane, C. Massey, J. E. Comer, A. N. Freiberg, H. Zhou, J. Dyall, M. Holbrook, M. Anantpadma, R. A. Davey, P. Madrid, S. Ekins

This paper evaluates pyronaridine tetraphosphate's efficacy against Ebola and Marburg viruses in guinea pigs, showing 40% survival and suggesting its potential for antiviral repurposing.

bioRxiv · Mar 20, 2020Pharmacology & Toxicology